CSBio CSBio

X
[{"orgOrder":0,"company":"Hugel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Croma Aesthetics Canada Launches Saypha\u00ae VOLUME PLUS","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Hugel"},{"orgOrder":0,"company":"Hugel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Croma Aesthetics Canada Ltd. Receives Canadian Market Authorization for Letybo (LetibotulinumtoxinA for Injection) for the Treatment of Glabellar Lines","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Hugel"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Presents Three-year Follow-up Data of Adalimumab Biosimilar SB5 in Patients with Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Samsung Bioepis"},{"orgOrder":0,"company":"Hugel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hugel's 'Letybo' First in Korea to Obtain Marketing Approval from Australia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Hugel"},{"orgOrder":0,"company":"Hugel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Croma Australia, a Subsidiary of Hugel Aesthetics, Receives TGA Approval in Australia for LETYBO (letibotulinumtoxinA) for the Treatment of Glabellar Lines","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Hugel"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics Completes Full Acquisition of Samsung Bioepis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Samsung Bioepis"},{"orgOrder":0,"company":"Dream CIS","sponsor":"Curi Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curi Bio, Genetox, and DreamCIS Sign MOU for Strategic Collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Dream CIS"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Through collaboration, DreamCIS will be supporting the clinical development with Curi Bio's cutting-edge neuromuscular junction model for advancing Genetox’s Botaone (clostridium botulinum toxin Type A) for Glabellar wrinkles and lateral canthal wrinkles.

            Lead Product(s): Clostridium Botulinum Toxin Type A

            Therapeutic Area: Dermatology Product Name: Botaone

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Curi Bio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 22, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            LETYBO is indicated for temporary improvement in the appearance of moderate to severe glabellar frown lines in adults. It is currently available in 28 countries worldwide, with recent approvals in Europe and Canada.

            Lead Product(s): LetibotulinumtoxinA

            Therapeutic Area: Dermatology Product Name: Letybo

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 28, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Hugel plans to effectively deliver the efficacy and safety of Letybo (letibotulinumtoxinA) by providing training for local medical staff and conducting academic programs in cooperation with major chain clinics and key opinion leaders.

            Lead Product(s): LetibotulinumtoxinA

            Therapeutic Area: Dermatology Product Name: Letybo

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 24, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Long-term real-world data on the effectiveness and safety of SB5 (adalimumab) biosimilars in psoriasis is limited, and study results from BADBIR demonstrate that SB5 is just as safe and effective as its reference adalimumab.

            Lead Product(s): Adalimumab

            Therapeutic Area: Dermatology Product Name: SB5

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 07, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Letybo (letibotulinumtoxinA for injection) for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity (frown lines between the eyebrows) in adult patients under 65 years of age.

            Lead Product(s): LetibotulinumtoxinA

            Therapeutic Area: Dermatology Product Name: Letybo

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 23, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The launch of saypha® VOLUME PLUS, a hyaluronic acid dermal filler, into the Canadian market will enhance the available line of saypha® dermal fillers, giving aesthetic medical professionals more creative power to design a truly bespoke experience for their patients.

            Lead Product(s): Hyaluronic Acid

            Therapeutic Area: Dermatology Product Name: Saypha

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Upon the acquisition of Biogen’s equity stake, companies will continue their agreement, including commercialization of products BENEPALI (etanercept), a biosimilar of ENBREL, IMRALDITM (adalimumab), a biosimilar of Humira and FLIXABI (infliximab), a biosimilar of Remicade.

            Lead Product(s): Etanercept

            Therapeutic Area: Dermatology Product Name: Benepali

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Samsung Biologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition April 20, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY